Board of Directors

Wolfgang Daum
Excecutive Chairman of the Board

Wolfgang is an executive and serial entrepreneur in healthcare (diagnostics, medical devices, and health services). Currently he serves as Chairman and CEO of TOMA Biosciences, Inc., a fast growing genomic cancer diagnostic company. Previously Wolfgang was President/CEO of companies Knome (genome interpretation), Castlewood Surgical (heart bypass surgery), Boston Heart Lab (heart diagnostic / Lipidology, and now under Bain one of the fastest growing diagnostic companies in the US), BrainVital (epilepsy), Thermonix (in-stent restenosis), CardioTools (angiography), and Daum (MRI); and relocated with a company acquisition from Germany to the US in 2001. Wolfgang holds a M.S. in Physics from University of Göttingen and a PhD from Technical University Hamburg-Harburg, both Germany. He is a Board member of medical company Precisis and an active angel investor with Launchpad Angels in Boston.

Paul Conley, PhD
Managing Director, Paladin Capital Group

Dr. Conley leads new investments for the firm while serving as an active Director on many of Paladin’s portfolio company boards. Paul joined the Paladin team after more than 15 years of previous R&D and entrepreneurial experience. As founding CEO of BrightScale, he led the commercialization of a patented multi-core microprocessor technology in the HDTV market. As founding CEO of Appfluent Technology, he led the commercialization of patented in-memory distributed database technologies in the enterprise IT market. Prior to taking the entrepreneurial route, he spent nearly a decade in multidisciplinary R&D roles in the areas of high-performance computing, applied physics, and biomedical engineering, including postdoctoral positions at the Los Alamos National Laboratory. Paul earned a PhD in Computational Physics and an MS in Bioengineering from UCSD, as well as an MS and BS in Mechanical and Aerospace Engineering from the University of Virginia.

Laurence J. Marton, MD

Dr. Marton serves as a consultant to industry and to nonprofit, governmental, and academic institutions. In the nonprofit sector, Dr. Marton serves on the Board of Trustees of the American Association for Cancer Research Foundation, and on the Board of Directors of Cancer Commons, Rapid Science, and the Bay Area American Committee for the Weizmann Institute of Science.  In the for-profit sector, he serves on the Board of Directors of TOMA Biosciences, RenovoRx, Microsonic Systems and Pathologica, is Chair of the Scientific Advisory Board of PharmaJet, is on the Advisory Boards of Gem Pharmaceuticals, Matternet, Silicom Ventures, and the PMWC, and on the Editorial Board of the Journal of Precision Medicine.

Previously, Dr. Marton was Dean of the University of Wisconsin Medical School and Chaired the Department of Laboratory Medicine at UCSF, where he was a Professor in the Departments of Laboratory Medicine and Neurological Surgery.  Dr. Marton received his MD from the Albert Einstein College of Medicine and his BA from Yeshiva University.

Mike Lucero
Chief Technology Officer, TOMA Biosciences

With over 25 years of experience helping to revolutionize life science tools, Mike leads the technology innovation and vision for TOMA. He was VP of PCR at Applied Biosystems (now Thermo Fisher) and has successfully built and developed multiple PCR platform tools including digital PCR and real time PCR. As an Executive VP at Fluidigm (FLDM), Mike was responsible for business development and product definition. He led the commercialization of technology at Stokes Bio as CEO, which was acquired by Applied Biosystems in 2010. Most recently, as VP of Sales and Marketing, Mike led commercialization for QuantaLife, which was acquired by Bio-Rad.

Brian Clevinger, Ph.D.

Brian Clevinger, Ph.D. is managing director of Prolog Ventures, an early stage venture capital firm focusing on life science start-ups in the Missouri region. Prolog has raised over $120M in three funds and has invested in over 35 health care companies, 16 of which were in St. Louis at the time of funding. Prior to Prolog, Dr. Clevinger was CEO of Megan Health, a vaccine company focused on food safety vaccines. He serves on the Board of the Center for Emerging Technologies, St. Louis Academy of Science, The Family Resource Center and a number of life science start-up companies. Dr. Clevinger holds a doctorate degree in immunology from Indiana University and was a post-doctoral fellow and tenured faculty member at Washington University, St. Louis, MO.